A New Strategy Regarding Discontinuation of Dual Antiplatelet; Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation (RESET Trial)

Trial Profile

A New Strategy Regarding Discontinuation of Dual Antiplatelet; Real Safety and Efficacy of a 3-month Dual Antiplatelet Therapy Following Zotarolimus-eluting Stents Implantation (RESET Trial)

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Zotarolimus (Primary) ; Aspirin; Clopidogrel; Everolimus; Sirolimus
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial infarction; Stent thrombosis; Unstable angina pectoris
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RESET
  • Most Recent Events

    • 04 Mar 2013 Planned number of patients changed from 2120 to 982 as reported by ClinicalTrials.gov.
    • 05 Sep 2012 Primary endpoint 'Cardiovascular-death-rate' has been met.
    • 03 Dec 2010 Planned end date changed from 1 Mar 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top